Experience of definitive chemoradiation for oesophageal cancer within a large regional cancer treatment centre: improving outcomes and tolerability.
Affiliation
Christie NHS Foundation Trust, Manchester, UKIssue Date
2018-07-26
Metadata
Show full item recordAbstract
To review delivery of definitive chemoradiation (dCRT) for patients with oesophageal cancer within a large regional cancer centre. To assess toxicity, tolerability and outcomes and compare with published data.Citation
Experience of definitive chemoradiation for oesophageal cancer within a large regional cancer treatment centre: improving outcomes and tolerability. 2018, Clin OncolJournal
Clinical OncologyDOI
10.1016/j.clon.2018.07.022PubMed ID
30057002Type
ArticleLanguage
enISSN
1433-2981ae974a485f413a2113503eed53cd6c53
10.1016/j.clon.2018.07.022
Scopus Count
Collections
Related articles
- Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
- Authors: Haisley KR, Hart KD, Nabavizadeh N, Bensch KG, Vaccaro GM, Thomas CR Jr, Schipper PH, Hunter JG, Dolan JP
- Issue date: 2017 Jul 1
- Neoadjuvant concurrent chemoradiotherapy followed by definitive high-dose radiotherapy or surgery for operable thoracic esophageal carcinoma.
- Authors: Murakami M, Kuroda Y, Okamoto Y, Kono K, Yoden E, Kusumi F, Hajiro K, Matsusue S, Takeda H
- Issue date: 1998 Mar 15
- A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
- Authors: Sanford NN, Catalano PJ, Enzinger PC, King BL, Bueno R, Martin NE, Hong TS, Wo JY, Mamon HJ
- Issue date: 2017 Jul 1
- Neoadjuvant versus adjuvant chemoradiation for stage II-III esophageal squamous cell carcinoma: a single institution experience.
- Authors: Chen Y, Hao D, Wu X, Xing W, Yang Y, He C, Wang W, Liu J, Wang J
- Issue date: 2017 Jul 1
- Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/- cetuximab in oesophageal cancer.
- Authors: Crosby T, Hurt CN, Falk S, Gollins S, Staffurth J, Ray R, Bridgewater JA, Geh JI, Cunningham D, Blazeby J, Roy R, Maughan T, Griffiths G, Mukherjee S
- Issue date: 2017 Mar 14